The abstract is read at the publisher; the summary is JClub's.
CAR immunotherapies are being developed for CNS proteinopathies to enable durable, programmable, aggregate-selective targeting while addressing limited brain exposure and inflammation-linked toxicity seen with amyloid-β antibodies.
- Why it matters: Neurodegenerative disorders feature abnormal protein aggregation and a dysregulated neuroimmune environment, but existing antibody immunotherapy in Alzheimer’s shows limited benefit due to low brain penetration, short-lived activity, repeated dosing needs, and inflammation-linked toxicity.
- What they did: This review surveys CAR strategies for aggregate-selective targeting in the CNS and discusses tunable controls and safety mechanisms, including how different CAR-engineered effector cell types could influence aggregate clearance and immune rebalancing.
- The result: The work outlines CAR design principles aimed at targeted immunomodulation with improved durability and programmability, supporting CNS-compatible immune programs that minimize collateral inflammation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.